

(51) International Patent Classification:
C12Q 1/68 (2006.01)(21) International Application Number:
PCT/AU2015/050096(22) International Filing Date:
11 March 2015 (11.03.2015)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
2014900813 11 March 2014 (11.03.2014) AU
2014901212 3 April 2014 (03.04.2014) AU
2014904716 21 November 2014 (21.11.2014) AU(71) Applicant: THE COUNCIL OF THE QUEENSLAND
INSTITUTE OF MEDICAL RESEARCH [AU/AU];
The Bancroft Centre, 300 Herston Road, Herston, Queens-
land 4029 (AU).(72) Inventor: AL-EJEH, Fares; c/o- THE COUNCIL OF
THE QUEENSLAND INSTITUTE OF MEDICAL RE-
SEARCH, The Bancroft Centre, 300 Herston Road, Her-
ston, Queensland 4029 (AU).(74) Agent: FISHER ADAMS KELLY PTY LTD; Level 29,
12 Creek Street, Brisbane, Queensland 4000 (AU).(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,
BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR,
KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG,
MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM,
PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC,
SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ,
TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU,
TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE,
DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU,
LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK,
SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— without international search report and to be republished
upon receipt of that report (Rule 48.2(g))

(54) Title: DETERMINING CANCER AGGRESSIVENESS, PROGNOSIS AND RESPONSIVENESS TO TREATMENT




FIG. 1





FIG. 1 cont'd

(57) Abstract: The invention provides methods of determining the aggressiveness, prognosis and response to therapy for particular cancers, which include comparing the expression levels of one or a plurality of differentially expressed genes from one or more 5 functional metagenes, including a Carbohydrate/Lipid Metabolism metagene, a Cell Signalling metagene, a Cellular Development metagene, a Cellular Growth metagene, a Chromosome Segregation metagene, a DNA Replication/Recombination metagene, an Immune system metagene, a Metabolic Disease metagene, a Nucleic Acid Metabolism metagene, a Post-Translational Modification metagene, a Protein 10 Synthesis/Modification metagene and a Multiple Networks metagene. The method disclosed herein may be particularly suitable as a companion diagnostic for cancer therapies.